The Quantellect read.As of Nov 19, 2026, 6 active firms cover Reviva Pharmaceuticals Holdings Inc: 4 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $2.00 to $4.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $2.67 sits 789% above the current $0.30. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy467%
Neutral233%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.67
+788.9% upside
Average target across 3 active firms as of Nov 19, 2026 vs $0.30 current
Highest Target$4.00
Average Target$2.67
Lowest Target$2.00
Detailed analyst forecasts for RVPH
Showing 1–4 of 4 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 4 of 6 active firms rate RVPH a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RVPH EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Reviva Pharmaceuticals Holdings Inc. to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-1.41, growing to $-1.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Reviva Pharmaceuticals Holdings Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RVPH.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$2.00+566.7% to target
Overall win rate
41%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$4.00+1233.3% to target
Overall win rate
36%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #487
Buy
$7.00+2233.3% to target
Overall win rate
36%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton RVPH
Overall win rate
22%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #567
Neutral
No targeton RVPH
Overall win rate
30%
+ Follow
RVPH stock forecast FAQ
What is RVPH's average 12-month price target?+
The 3 active firms with a live target average $2.67 for Reviva Pharmaceuticals Holdings Inc. over the next 12 months, ranging from a $4.00 high to a $2.00 low, as of Nov 19, 2026.
Is RVPH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RVPH?+
The Street-high target is $4.00 (HC Wainwright & Co.), and the Street-low is $2.00 (Chardan Capital). The average of all 3 active-firm targets is $2.67.
How many active Wall Street firms cover RVPH?+
6 active firms have a recognized rating on Reviva Pharmaceuticals Holdings Inc. as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RVPH?+
Among analysts who currently cover RVPH, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $2.00 target.
What is Reviva Pharmaceuticals Holdings Inc.'s projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $-1.41, rising to $-1.44 the following year.
How much revenue is Reviva Pharmaceuticals Holdings Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading RVPH lately?+
As of Nov 19, 2026, 4 of 6 active firms rate RVPH a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RVPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.